Octapharma USA Research Results Presented at HTRS Symposium Targeting Major Challenges Facing Hemophilia Patients
Global Clinical Trials Focus on Inhibitor Development, Dosing Frequency
Octapharma USA Sponsors ‘Hope Ignites: Stories to Inspire’ Program at Hemophilia Federation of America Annual Symposium
HOBOKEN, N.J. (April 7, 2017) – Octapharma USA today sponsored the patient symposium “Hope Ignites: Stories to Inspire,” during the Hemophilia Federation of America (HFA) Annual Symposium in Providence, Rhode Island....
HOBOKEN, N.J. (March 22, 2017) – Octapharma USA has awarded an educational grant to the Global Blood Disorder Foundation (GBDF) to sponsor the first national conference for patients with Type 3 von Willebrand Disease...
Octapharma Group publishes 2016 annual results reporting revenue of €1.6 billion and operating income of €383 million
Lachen, Switzerland, March 1st, 2017: The Octapharma Group can report a record-breaking result with sales of €1.6 billion, which represents an increase of €87 million or 5.8% compared with 2015. Octapharma achieved sales...